z-logo
open-access-imgOpen Access
Metformin Role in Diabetic Patients with Tuberculosis: a Review
Author(s) -
Esravila Ariya Wibisono
Publication year - 2021
Publication title -
journal of tropical pharmacy and chemistry
Language(s) - English
Resource type - Journals
eISSN - 2407-6090
pISSN - 2087-7099
DOI - 10.25026/jtpc.v5i3.275
Subject(s) - medicine , metformin , tuberculosis , incidence (geometry) , sputum , diabetes mellitus , comorbidity , population , type 2 diabetes mellitus , immunology , intensive care medicine , environmental health , pathology , physics , optics , endocrinology
Tuberculosis (TB) epidemic is a global health challenge, and WHO estimated the incidence of the new cases reaching 11.1 million people in 2017. Indonesia is classified as a high TB burden country, with 8% of its population infected by TB and ranks third in the world. Type-2 diabetes mellitus (T2DM) is known comorbidity for TB patients. TB-T2DM patients have a higher chance of morbidity, mortality, relapse, bacterial resistance, treatment failure, and slower sputum conversion than TB patients without T2DM. Recent studies suggest that metformin may have a potential synergistic role for TB-T2DM patients. Metformin has immunomodulator properties that can improve the body's immune response and inflammatory response against TB in individuals with T2-DM.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom